Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

Open access
Mendell, Jerry R., Muntoni, Francesco, McDonald, Craig M., Mercuri, Eugenio M., Ciafaloni, Emma, Komaki, Hirofumi, Leon-Astudillo, Carmen, Nascimento, Andrés, Proud, Crystal, Schara-Schmidt, Ulrike, Veerapandiyan, Aravindhan, Zaidman, Craig M., Guridi, Maitea, Murphy, Alexander P., Reid, Carol, Wandel, Christoph, Asher, Damon R., Darton, Eddie, Mason, Stefanie, Potter, Rachael A., Singh, Teji, Zhang, Wenfei, Fontoura, Paulo, Elkins, Jacob S., Rodino-Klapac, Louise R. · 2025 · Nature Medicine

Abstract

Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by pathogenic variants in the DMD gene that result in the absence of functional dystrophin, beginning at birth and leading to progressive impaired motor function, loss of ambulation and life-threatening cardiorespiratory complications. Delandistrogene moxeparvovec, an adeno-associated rh74-viral vector-based gene therapy, addresses absent functional dystrophin in DMD. Here the phase 3 EMBARK study aimed to assess the efficacy and safety of delandistrogene moxeparvovec in patients with DMD. Ambulatory males with DMD, ≥4 years to <8 years of age, were randomized and stratified by age group and North Star Ambulatory Assessment (NSAA) score to single-administration intravenous delandistrogene moxeparvovec (1.33 × 1014 vector genomes per kilogram; n = 63) or placebo (n = 62). At week 52, the primary endpoint, change from baseline in NSAA score, was not met (least squares mean 2.57 (delandistrogene moxeparvovec) versus 1.92 (placebo) points; between-group difference, 0.65; 95% confidence interval (CI), −0.45, 1.74; P = 0.2441). Secondary efficacy endpoints included mean micro-dystrophin expression at week 12: 34.29% (treated) versus 0.00% (placebo). Other secondary efficacy endpoints at week 52 (between-group differences (95% CI)) included: Time to Rise (−0.64 (−1.06, −0.23)), 10-meter Walk/Run (−0.42 (−0.71, −0.13)), stride velocity 95th centile (0.10 (0.00, 0.19)), 100-meter Walk/Run (−3.29 (−8.28, 1.70)), time to ascend 4 steps (–0.36 (−0.71, −0.01)), PROMIS Mobility and Upper Extremity (0.05 (−0.08, 0.19); −0.04 (−0.24, 0.17)) and number of NSAA skills gained/improved (0.19 (−0.67, 1.06)). In total, 674 adverse events were recorded with delandistrogene moxeparvovec and 514 with placebo. There were no deaths, discontinuations or clinically significant complement-mediated adverse events; 7 patients (11.1%) experienced 10 treatment-related serious adverse events. Delandistrogene moxeparvovec did not lead to a significant improvement in NSAA score at week 52. Some of the secondary endpoints numerically favored treatment, although no statistical significance can be claimed. Safety was manageable and consistent with previous delandistrogene moxeparvovec trials. ClinicalTrials.gov: NCT05096221 The primary report of the EMBARK phase 3 trial, testing the AAV-based gene therapy delandistrogene moxeparvovec in Duchenne muscular dystrophy, did not meet its primary endpoint of improvement in NSAA mobility scores compared to placebo. Secondary endpoints show that the therapy was safe and associated with improvements in micro-dystrophin expression and in individual mobility scores.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03304-z

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Metadata

Authors
Mendell, J. R., Muntoni, F., McDonald, C. M., Mercuri, E. M., Ciafaloni, E., Komaki, H., Leon-Astudillo, C., Nascimento, A., Proud, C., Schara-Schmidt, U., Veerapandiyan, A., Zaidman, C. M., Guridi, M., Murphy, A. P., Reid, C., Wandel, C., Asher, D. R., Darton, E., Mason, S., Potter, R. A., Singh, T., Zhang, W., Fontoura, P., Elkins, J. S., & Rodino-Klapac, L. R.
Venue
Nature Medicine
Published
2024-10-09
Volume
31
Issue
1
Pages
332-341
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4403275986
Cited by
183
References
5
FWCI
44.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. https://app.cochat.ai/papers/10.1038/s41591-024-03304-z
The paper
Mendell, J. R., Muntoni, F., McDonald, C. M., Mercuri, E. M., Ciafaloni, E., Komaki, H., Leon-Astudillo, C., Nascimento, A., Proud, C., Schara-Schmidt, U., Veerapandiyan, A., Zaidman, C. M., Guridi, M., Murphy, A. P., Reid, C., Wandel, C., Asher, D. R., Darton, E., Mason, S., . . . Rodino-Klapac, L. R. (2025). AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03304-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.